Trial Profile
Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Anthracyclines (Primary) ; Eribulin (Primary) ; Taxanes (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 23 Sep 2021 Results assessing the clinical response rate and safety of patients with advanced, local, HER2-negative breast cancer to sequential therapy with anthracycline, taxane, and eribulin, published in the Breast Cancer Research and Treatment.
- 08 Jul 2021 Planned End Date changed from 31 May 2025 to 27 May 2019.
- 08 Jul 2021 Status changed from active, no longer recruiting to discontinued.